Epiomic Epidemiology Series: Addison’s Disease Forecast In 22 Major Markets 2018-2028 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 19, 2018--The “Epiomic Epidemiology Series: Addison’s Disease Forecast In 22 Major Markets 2018-2028” report has been added to ResearchAndMarkets.com’s offering.Addison’s disease (AD) is a chronic and rare endocrinal disorder, caused by destruction of the adrenal cortex which leads to the reduced production of glucocorticoids, mineralocorticoids and adrenal androgens. Chronic adrenal insufficiency and hypersecretion of ACTH is representative of the basic clinical signs and symptoms. AD can be part of the autoimmune polyglandular syndrome (PAS) (type 1 and 2), or it may present as an isolated disorder. PAS usually also affects other endocrine glands including the thyroid, pancreatic beta cells and stomach cells that allow absorption of vitamin B12 (producing pernicious anaemia).
This report provides the current prevalent population for AD across 22 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Norway, Sweden, Iceland, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the publisher’s analysis team, AD patients grouped by disease classification and comorbidities have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities of AD include:Autoimmune thyroiditis (AT)Type 1 diabetes (T1D)AnaemiaVitiligoChronic fatiguePremature ovarian failureHypopigmentation
Reasons to buyAbility to quantify patient populations in global AD market to target the development of future products, pricing strategies and launch plans.Further insight into the prevalence of the subdivided types of AD and identification of patient segments with high potential.Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.Better understanding of the impact of specific co-morbid conditions on the prevalent population of AD patients.Identification of AD patient sub-populations that require treatment.Better understanding of the specific markets that have the largest number of AD patients.
Key Topics Covered:List Of Tables And FiguresIntroductionCause Of The DiseaseRisk Factors & PreventionDiagnosis Of The DiseaseVariation By Geography/EthnicityDisease Prognosis & Clinical CourseKey Comorbid Conditions / Features Associated With The DiseaseMethodology For Quantification Of Patient NumbersTop-Line Prevalence For Addison’s DiseaseFeatures Of Addison’s Disease PatientsComorbidities Of Addison’s Disease PatientsAbbreviations Used In The ReportOther Publisher Services & SolutionsReports & PublicationsOnline Epidemiology DatabasesOnline Pharmaceutical Pricing DatabaseReferencesAppendixFor more information about this report visit https://www.researchandmarkets.com/research/jgx2j4/epiomic?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180919005616/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Endocrine and Metabolic Disorders Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/19/2018 12:33 PM/DISC: 09/19/2018 12:33 PM